U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06884904) titled 'Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF' on March 13.
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled adaptive design Phase IIb/III clinical trial. It employs a seamless adaptive design, divided into Phase IIb and Phase III, focusing on patients with acute-on-chronic liver failure (ACLF). Eligible patients meeting the inclusion criteria and not disqualified were randomized in a 2:2:1:1 ratio during Phase IIb to receive either a high-dose experimental group (4.0x10^6/kg of injectable mesenchymal stem cells derived from umbilical cord), a low-dose group (2.0x10^...